Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: A phase I study

International Journal of Clinical Oncology

Volumn 10, Issue 4, 2005, Pages 251-255

  Shimoyama, Shouji ^a   Imamura, Kazuhiro ^a   Hiki, Naoki ^a   Yamaguchi, Hirokazu ^a   Mafune, Ken Ichi ^a   Kaminishi, Michio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Advanced gastric cancer; Chemotherapy; Cisplatin; Phase I Study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; FEMALE; FRACTIONATION; HUMAN; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR;

EID: 24144436654     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-005-0505-x     Document Type: Article

References (21)

1. RT Greenlee T Murray S Bolden 2000 Cancer statistics 2000 CA Cancer J Clin 50 7 33
2. B Glimerius K Ekström K Hoffman 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 1 6
3. K Sugimachi Y Maehara N Horikoshi 1999 An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointesitnal cancers Oncology 57 202 210
4. Y Sakata A Ohtsu N Horikoshi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1∈M tegafur - 0.4∈M gimestat - 1∈M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720
5. W Koizumi M Kurihara S Nakano 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191 197
6. S Shimoyama F Aoki T Murakami 2000 The feasibility of daily concurrent chemoradiation therapy as a nonsurgical management for esophageal cancer: our experience and theoretical backgrounds J Surg Oncol 74 134 137
7. T Shirasaka Y Shimamoto H Ohshimo 1993 Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo Cancer Chemother Pharmacol 32 167 172
8. Y-S Chung Y Yamashita T Inoue 1997 Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma Cancer 80 1 7
9. A Ohtsu Y Shimada S Yoshida 1994 Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer. Report from the Japan Clinical Oncology Group (JCOG) Eur J Cancer 30A 2091 2093
10. W Koizumi S Tanabe K Saigenji 2003 Phase I/II studyof S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212
11. MM Oken RH Creech DC Tormey 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649 655
12. A Trotti R Byhardt J Stetz 2000 Common toxicity criteria version 2.0: an improved reference for grading the acute effects of cancer treatment. Impact on radiology Int J Radiat Oncol Phys 47 13 47
13. G Liu E Franssen MI Fitch 1997 Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 110 115
14. I Hyodo T Nishina T Moriwaki 2003 A phase I study ofS-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting Eur J Cancer 39 2328 2333
15. L Leichman B McDonald A Dindogru 1984 An active drug in the treatment of disseminated gastric cancer Cancer 53 18 22
16. RC DeConti BR Toftness RC Lange 1973 Clinical and pharmacological studies with cis-diamminedichloroplatinum (II) Cancer Res 33 1310 1315
17. CJ van Groeningen GJ Peters JH Schomagel 2000 Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors J Clin Oncol 18 2772 2779
18. T Taguchi Y Inuyama R Kanamaru 1997 Phase I study of S-1 Jpn J Cancer Chemother 24 2253 2264
19. N Kurihara T Kubota Y Hoshiya 1996 Antitumor activity of cis-diamminedichloroplatinum (II) against human tumor xenografts depends on its area under the curve in nude mice J Surg Oncol 61 138 142
20. A Russo V Gebbia S Palmeri 1993 Results of thecombination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma Eur J Gynaecol Oncol 14 228 233
21. MP Corder TE Elliott SJ Bell 1977 Dose limiting myelotoxicity in absence of significant nephrotoxicity with a weekly outpatient schedule of cisplatinum (II) diamminedichloride J Clin Hematol Oncol 7 645 651